InfuSystem Holdings, Inc
No enriched coverage for $INFU in the last 7 days.
No SEC Form 4 filings for $INFU in the last 30 days.
See all $INFU insider activity →InfuSystem (INFU) reported Q2 2026 revenue of $36.9 million, up 2.6% year over year, including a $1.6 million revenue reduction from a GE Healthcare biomedical services contract restructuring. Adjusted EBITDA rose 7.6% to $8.6 million, with margin at 23.4%. Oncology revenue grew 6.4% and Wound Care rose 154%. The company expects 2026 pro forma revenue growth of 6% to 8% and adjusted EBITDA margin in the low-to-mid 20% range.
InfuSystem Holdings reported Q2 2026 revenue of $36.9 million, up 154% year over year in Wound Care and with 6.4% growth in core Oncology. The company restructured a GE Healthcare biomedical services contract, reducing GAAP revenue by $1.6 million, and raised adjusted EBITDA margin to 23.4%. Guidance keeps pro forma revenue growth at 6% to 8% and EBITDA margins in the low to mid-20% range.
Biotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
Recent INFU coverage spans financial news, earnings and market movers.
Earnings call provides fresh operating datapoints and a forward-looking pro forma revenue growth range, with margin expectations anchored to low-to-mid 20% adjusted EBITDA.
Earnings-call disclosures point to improving profitability via the GE contract pivot, offset by device revenue declines and ERP spending taper.
Guidance plus segment mix (Patient Services up, Device Solutions down) is the core driver for the sharp move.
Q2 results show modest revenue growth with margin expansion, plus a reaffirmed full-year outlook, which can drive near-term positioning around guidance credibility.
Analyst optimism suggests potential upward movement for INFU.
alphai scores every news story that mentions INFU with an AI model for sentiment and relevance, and aggregates insider trades from InfuSystem Holdings, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
InfuSystem (INFU) reported Q2 2026 revenue of $36.9 million, up 2.6% year over year, including a $1.6 million revenue reduction from a GE Healthcare biomedical services contract restructuring. Adjusted EBITDA rose 7.6% to $8.6 million, with margin at 23.4%. Oncology revenue grew 6.4% and Wound Care rose 154%. The company expects 2026 pro forma revenue growth of 6% to 8% and adjusted EBITDA margin in the low-to-mid 20% range.
6 min readInfuSystem Holdings reported Q2 2026 revenue of $36.9 million, up 154% year over year in Wound Care and with 6.4% growth in core Oncology. The company restructured a GE Healthcare biomedical services contract, reducing GAAP revenue by $1.6 million, and raised adjusted EBITDA margin to 23.4%. Guidance keeps pro forma revenue growth at 6% to 8% and EBITDA margins in the low to mid-20% range.
6 min readBiotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
6 min readInfuSystem Holdings, Inc (INFU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact: Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces Financial Results for Second Quarter 2026 Net Revenues of $36.9 million Representing a 2.6% Increa
6 min readHealthcare analysts have provided optimistic insights on InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN). Craig-Hallum maintained a Buy rating on InfuSystem Holdings with a significant upside, while J.P. Morgan initiated coverage on BioMarin Pharmaceutical with a Buy rating and a set price target. Both companies show strong analyst consensus ratings.
2 min readInfuSystem Holdings, Inc.'s EVP and CIO, Addam Chupa, reported an update to his shareholdings and new equity awards, including 47,210 directly held common shares. He received 9,973 restricted stock units (RSUs) and 20,777 stock options with an exercise price of $8.37 per share. Both the RSUs and stock options begin vesting in equal annual installments starting May 12, 2027.
2 min readInfuSystem Holdings director Beverly A. Huss reported receiving a stock option grant for 24,890 shares, with an exercise price of $8.37 per share. The options will vest on May 12, 2027, and expire on May 12, 2036. This grant represents compensation and not an open-market transaction, adding to her direct holding of 4,300 common shares.
2 min readInfuSystem Holdings, Inc. announced the results of its 2026 annual stockholder meeting, including the approval of a Third Amendment to its 2021 Equity Incentive Plan, increasing the shares reserved for issuance to 7,000,000. Stockholders re-elected all seven Board nominees, approved executive compensation on an advisory basis, and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. This 8-K filing details these governance and compensation decisions.
2 min readThe consensus price target hints at a 40% upside potential for InfuSystems Holdings (INFU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 min readHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 min read
